Jan 9 2010
The Biotechnology Industry Organization (BIO) today announced the 
      selection of therapeutic workshops to be presented at the Twelfth Annual 
      BIO CEO & Investor Conference, taking place February 8-9 at the>
“This conference provides industry executives, 
      clinical thought leaders and investment professionals the opportunity to 
      discuss therapeutic areas of need and expectations for the next decade’s 
      market environment.”
    
      “This year’s BIO CEO & Investor Conference will provide a unique forum 
      to showcase therapeutic areas with key catalysts – from new and dynamic 
      therapies to cutting edge investment opportunities,” said Alan 
      Eisenberg, executive vice president of Emerging Companies & Business 
      Development at BIO. “This conference provides industry executives, 
      clinical thought leaders and investment professionals the opportunity to 
      discuss therapeutic areas of need and expectations for the next decade’s 
      market environment.”
    
    
      This year, BIO is collaborating with Panel Intelligence (formerly 
      MedPanel), a healthcare market research firm, to identify key opinion 
      leaders based on knowledge and expertise in their respective fields and 
      affiliations with prestigious academic institutions and medical 
      foundations.
    
    
      The BIO CEO & Investor Conference’s therapeutic workshops will focus on 
      topics addressing the latest developments in therapies for a wide range 
      of diseases. This year’s therapeutic workshop topics include:
    
    
      Sarcoma: Connecting the Dots on New Therapies
Monday, 
      February 8th, 9:00am-10:00am
    
    
      - 
        John G. Curd, M.D.; President and Chief Medical Officer, Threshold 
        Pharmaceuticals
      
 
      - 
        Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical 
        Officer, ZIOPHARM Oncology
      
 
      - 
        Robert G. Maki, M.D., Ph.D; Associate Member, Co-Leader, Adult Sarcoma 
        Program, Memorial Sloan-Kettering Cancer Center
      
 
    
    
      RNAi Based Technology: No Longer Single & Stranded
Monday, 
      February 8, 12:30-1:35pm
    
    
      - 
        Simos Simeonidis, PhD; Managing Director, Rodman & Renshaw, LLC
      
 
      - 
        Noah D. Beerman, President and Chief Executive Officer, RXi 
        Pharmaceuticals
      
 
      - 
        J. Michael French; Chief Executive Officer, MDRNA
      
 
      - 
        Alnylam Pharmaceuticals
      
 
    
    
      Alzheimer’s Disease: A Panel to Remember
Tuesday, 
      February 9th, 9:00am-10:00am
    
    
      - 
        Tony Cruz, MD; Chief Executive Officer, Transition Therapeutics
      
 
      - 
        David Hung, MD; President & Chief Executive Officer, Medivation
      
 
      - 
        Carlos V. Paya, MD; PhD, President, Elan
      
 
      - 
        Alzheimer’s Association
      
 
      - 
        Steven Ferris, PhD; Friedman Professor and Director of Alzheimer’s 
        Disease Center, Center of Excellence on Brain Agin, New York 
        University Langone Medical Center
      
 
    
    
      HCV: Liver Long & Prosper
Tuesday, February 9, 
      12:00pm-1:00pm
    
    
      - 
        M. Michelle Berrey, M.D., M.P.H.; Chief Medical Officer, Pharmasset
      
 
      - 
        Robert S. Kauffman, M.D., Ph.D, Chief Medical Officer and Senior Vice 
        President Clinical Development
      
 
      - 
        Steve Worland, Ph.D.,; President & Chief Executive Officer, Anadys 
        Pharmaceuticals
      
 
      - 
        Douglas T. Dieterich, M.D.; Professor of Medicine, Director of 
        Outpatient Hepatology in the Division of Liver Diseases and Director 
        of CME in the Department of Medicine, Mount Sinai School of Medicine
      
 
    
    
      Lupus: New Care for Too Much Flare
Tuesday, February 9th, 
      3:00pm-4:00pm
    
    
      - 
        Mark Schoenebaum, MD; Managing Director & Senior Biotechnology 
        Analyst, Deutsche Bank
      
 
      - 
        Barry A. Labinger, Executive Vice President & Chief Commercial 
        Officer, Human Genome Sciences
      
 
      - 
        Sandra C. Raymond, President and Chief Executive Officer, Lupus 
        Foundation of America
      
 
      - 
        Richard Furie, M.D.; Chief of the Division of Rheumatology & 
        Allergy-Clinical Immunology, North Shore-Long Island Jewish Health 
        System
      
 
    
http://www.bio.org/